Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats

Menopause

Volumn 20, Issue 8, 2013, Pages 860-868

  Jessup, Jewell A ^a   Wang, Hao ^a   Macnamara, Lindsay M ^a   Presley, Tennille D ^b,c   Kim Shapiro, Daniel B ^c   Zhang, Lili ^d   Chen, Alex F ^d,e   Groban, Leanne ^a,c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WINSTON SALEM STATE UNIVERSITY   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiac biopterins; Diastolic dysfunction; Estrogen timing; Left ventricular remodeling; Menopause; Nitrite

Indexed keywords

DIHYDROBIOPTERIN; ESTRADIOL; NITRIC OXIDE;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HEART FUNCTION; HEART MUSCLE; HYPERTENSION; NONHUMAN; OVARIECTOMY; RANDOMIZATION; RAT; TISSUE DOPPLER IMAGING; TISSUE STRUCTURE; VELOCITY;

EID: 84881371108     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318280589a     Document Type: Article

References (61)

1. Hayward CS, Kalnins WV, Kelly RP. Gender-related differences in left ventricular chamber function. Cardiovasc Res 2001;49: 340-350. (Pubitemid 32119551)
2. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006;5: 425-438.
3. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007;49: 241-251. (Pubitemid 44932176)
4. Wong DT, Clark RA, Dundon BK, Philpott A, Molaee P, Shakib S. Caveat anicula! Beware of quiet little old ladies: demographic features, pharmacotherapy, readmissions and survival in a 10-year cohort of patients with heart failure and preserved systolic function. Med J Aust 2010;192: 9-13.
5. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43: 317-327. (Pubitemid 38167688)
6. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41: 217-223. (Pubitemid 36092188)
7. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362: 777-781. (Pubitemid 37093918)
8. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359: 2456-2467.
9. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289: 194-202. (Pubitemid 36068707)
10. Banks E, Canfell K. Invited Commentary: Hormone therapy risks and benefitsVthe Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Am J Epidemiol 2009;170: 24-28.
11. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/progestin Replacement Study: lessons learned. Circulation 2002;105: 917-922. (Pubitemid 34184567)
12. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 2012;135: 54-70.
13. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280: 605-613. (Pubitemid 28502636)
14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333. (Pubitemid 34761611)
15. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348: 645-650. (Pubitemid 36204960)
16. Dubey RK, Imthurn B, Barton M, Jackson EK. Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 2005;66: 295-306. (Pubitemid 40471044)
17. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 2007;166: 506-510. (Pubitemid 47283648)
18. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8: 3-12. (Pubitemid 40675116)
19. Groban L, Pailes NA, Bennett CD, et al. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 2006;61: 28-35. (Pubitemid 43227799)
20. Jessup JA, Zhang L, Chen AF, et al. Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2.Lewis rats. Menopause 2011;18: 698-708.
21. Jessup JA, Zhang L, Presley TD, et al. Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2.Lewis rats. Endocrinology 2011;152: 2428-2436.
22. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, Groban L. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res 2012;94: 96-104.
23. Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2.Lewis rat. Hypertension 2003;42: 781-786. (Pubitemid 37237325)
24. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MC. Ovariectomy is protective against renal injury in the highsalt- fed older mRen2.Lewis rat. Am J Physiol Heart Circ Physiol 2007;293:H2064-H2071. (Pubitemid 47605842)
25. Chappell MC, Westwood BM, Yamaleyeva LM. Differential effects of sex steroids in young and aged female mRen2.Lewis rats: a model of estrogen and salt-sensitive hypertension. Gend Med 2008;5(suppl A): S65-S75. (Pubitemid 351455232)
26. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006;290:H2417-H2423. (Pubitemid 43846070)
27. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
28. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 1993;91: 2479-2487. (Pubitemid 23182499)
29. Lam KK, Lee YM, Hsiao G, Chen SY, Yen MH. Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause 2006;13: 294-302.
30. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35: 790-796. (Pubitemid 37329482)
31. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem 2003;251: 89-95. (Pubitemid 37220714)
32. Kolodgie FD, Farb A, Litovsky SH, et al. Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. J Mol Cell Cardiol 1997;29: 2403-2414. (Pubitemid 27404433)
33. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2003;284:H1560-H1569. (Pubitemid 36460767)
34. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 1999;131: 463-466.
35. Garcia PM, Giménez J, Bonacasa B, et al. 17A-Estradiol exerts a beneficial effect on coronary vascular remodeling in the early stages of hypertension in spontaneously hypertensive rats. Menopause 2005;12: 453-459. (Pubitemid 41098659)
36. Sharkey LC, Holycross BJ, Park S, et al. Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failureYprone SHHF/Mccj fa cp rats. J Mol Cell Cardiol 1999;31: 1527-1537. (Pubitemid 29361119)
37. Crofton JT, Share L. Gonadal hormones modulate deoxycorticosteronesalt hypertension in male and female rats. Hypertension 1997;29: 494-499. (Pubitemid 27074089)
38. Sasaki T, Ohno Y, Otsuka K, Suzawa T, Suzuki H, Saruta T. Oestrogen attenuates the increases in blood pressure and platelet aggregation in ovariectomized and salt-loaded Dahl saltYsensitive rats. J Hypertens 2000;18: 911-917. (Pubitemid 30459493)
39. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005;45: 1050-1055. (Pubitemid 40770302)
40. Thom S. Arterial structural modifications in hypertension. Effects of treatment. Eur Heart J 1997;18(suppl E):E2-E4.
41. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G proteinYcoupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009;150: 3753-3758.
42. Babiker FA, De Windt LJ, van Eickels M, et al. 17A-Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptorYcyclic guanosine monophosphateYdependent protein kinase pathway. Circulation 2004;109: 269-276. (Pubitemid 38114150)
43. Koshman YE, Piano MR, Russell B, Schwertz DW. Signaling responses after exposure to 5>-dihydrotestosterone or 17A-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytes. J Appl Physiol 2010;108: 686-696.
44. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 2005;280: 26339-26348. (Pubitemid 41022232)
45. Pechenino AS, Lin L, Mbai FN, et al. Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation. Physiol Genomics 2011;43: 1065-1073.
46. Miyazaki-Akita A, Hayashi T, Ding QF, et al. 17A-Estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose: relevance to postmenopausal diabetic cardiovascular disease. J Pharmacol Exp Ther 2007;320: 591-598. (Pubitemid 46147938)
47. Susic D, Varagic J, Frohlich ED. Coronary circulation in hypertension and aging: an experimental study. Ochsner J 2008;8: 5-10. (Pubitemid 351731899)
48. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28: 483-490. (Pubitemid 41195386)
49. Inoue T, Morooka S, Hayashi T, Takayanagi K, Sakai Y, Takabatake Y. Left ventricular diastolic dysfunction in coronary artery disease: effects of coronary revascularization. Clin Cardiol 1992;15: 577-581.
50. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 2003; 57: 388-394. (Pubitemid 36144217)
51. Zhou L, Shao Y, Huang Y, Yao T, Lu LM. 17A-Estradiol inhibits angiotensin IIYinduced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol 2007;567: 186-192. (Pubitemid 46976891)
52. Fak AS, Erenus M, Tezcan H, Caymaz O, Oktay S, Oktay A. Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction. Fertil Steril 2000;73: 66-71. (Pubitemid 30018024)
53. Alecrin IN, Aldrighi JM, Caldas MA, Gebara OC, Lopes NH, Ramires JA. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. Heart 2004;90: 777-781. (Pubitemid 38813639)
54. Duzenli MA, Ozdemir K, Sokmen A, et al. The effects of hormone replacement therapy on myocardial performance in early postmenopausal women. Climacteric 2010;13: 157-170.
55. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 3040-3043. (Pubitemid 47236368)
56. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. The follicle-deplete mouse ovary produces androgen. Biol Reprod 2004;71: 130-138. (Pubitemid 38915317)
57. Frye JB, Lukefahr AL, Wright LE, Marion SL, Hoyer PB, Funk JL. Modeling perimenopause in Sprague-Dawley rats by chemical manipulation of the transition to ovarian failure. Comp Med 2012;62: 193-202.
58. Groban L, Jobe H, Lin M, Houle T, Kitzman DA, Sonntag W. Effects of short-term treadmill exercise training or growth hormone supplementation on diastolic function and exercise tolerance in old rats. J Gerontol A Biol Sci Med Sci 2008;63: 911-920.
59. Molmen HE, Wisloff U, Aamot IL, Stoylen A, Ingul CB. Aerobic interval training compensates age related decline in cardiac function. Scand Cardiovasc J 2012;46: 163-171.
60. Tanaka H, DeSouza CA, Seals DR. Absence of age-related increase in central arterial stiffness in physically active women. Arterioscler Thromb Vasc Biol 1998;18: 127-132. (Pubitemid 28047609)
61. Flues K, Paulini J, Brito S, et al. Exercise training associated with estrogen therapy induced cardiovascular benefits after ovarian hormones deprivation. Maturitas 2010;65: 267-271.